

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
UNITED STATES

Physician: arup, arup

Patient: Prod test, SKEL PANEL 5

DOB

Sex: Female

Patient Identifiers: 41765

Visit Number (FIN): 42090

Collection Date: 8/17/2022 12:04

Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication

ARUP test code 2012015

Skeletal Dysplasia Panel Specimen	whole Blood
Skeletal Dysplasia Panel Interp	<p>Negative</p> <p>RESULT No pathogenic variants were detected in any of the genes tested.</p> <p>INTERPRETATION No pathogenic variants were identified by massively parallel sequencing of the coding regions and exon-intron boundaries of the genes tested. No large exonic deletions and duplications were identified in the genes tested. This result decreases, but does not exclude, a diagnosis of a skeletal dysplasia. Please refer to the background information included in this report for a list of the genes analyzed and limitations of this test.</p> <p>RECOMMENDATIONS Medical screening and management should rely on clinical findings and family history. Genetic consultation is recommended.</p> <p>COMMENTS Likely benign and benign variants are not reported. Variants in the following regions may not be detected by NGS with sufficient confidence in this sample due to technical limitations; reportable variants are confirmed by Sanger sequencing: NONE</p> <p>BACKGROUND INFORMATION: Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication</p> <p>CHARACTERISTICS: Skeletal dysplasias are a heterogeneous group of more than 400 disorders characterized by abnormal growth of cartilage or bone. Clinical features may include shortening, bowing, fracturing, thinning, thickening, or under mineralization of the bones; abnormal ribs; small chest circumference; and extra fingers or toes. Some disorders may be detectable prenatally, while others are not identified until birth or later childhood.</p> <p>EPIDEMIOLOGY: Collective incidence of 1 in 5000</p> <p>CAUSE: Pathogenic germline variants in genes associated with cartilage and bone growth</p> <p>INHERITANCE: Contingent on etiology; autosomal recessive, autosomal dominant, and X-linked inheritance, depending on the causative gene</p> <p>CLINICAL SENSITIVITY: Dependent on the specific skeletal dysplasia; 99 percent for achondroplasia and thanatophoric dysplasia; greater than 95 percent for COL1A1/2 osteogenesis imperfecta; greater than 90 percent for achondrogenesis type 1B, diastrophic dysplasia, and campomelic dysplasia.</p> <p>GENES TESTED: AGPS, ALPL, ARSL, CANT1, CCN6, CILK1, COL1A1,</p>

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Prod test, SKEL PANEL 5
ARUP Accession: 22-229-107802
Patient Identifiers: 41765
Visit Number (FIN): 42090
Page 1 of 3 | Printed: 8/17/2022 12:56:19 PM

COL1A2, * COL2A1, COL10A1, COL11A1, COL11A2, COMP, CRTAP, DDR2, DLL3, DYM, * DYNC2H1, EBP, EVC, * EVC2, FGFR1, * FGFR2, FGFR3, FKBP10, FLNA, FLNB, GDF5, GNPAT, HSPG2, IFT80, INPPL1, LBR, LIFR, NEK1, * NPR2, P3H1, PCNT, PEX7, POR, * PPIB, PTH1R, RUNX2, SERPINH1, SLC26A2, SLC35D1, SMARCAL1, SOX9, TRIP11, TRPV4, TTC21B, WDR19, WDR35

*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see limitations section below.

METHODOLOGY: Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and to confirm reported variants that do not meet acceptable quality metrics. A proprietary bioinformatic algorithm was used to detect large (single exon-level or larger) deletions or duplications in the indicated genes. Large deletions/duplications confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY: The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (indels) from 1-10 base pairs in size. Indels greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of 2 exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of 3 exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

LIMITATIONS: A negative result does not exclude diagnosis of a skeletal dysplasia. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Variants in the chr17:70,119,704-70,119,743 region of SOX9 exon 3 may not be detected. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified, including deletions/duplications in the upstream regulatory region of SOX9. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect duplications of 2 or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

The following regions are not sequenced due to technical limitations of the assay:
EVC(NM_153717) exon(s) 1

Single exon deletions/duplications will not be called for the following exons:
COL1A2(NM_000089) 3; EVC (NM_153717) 1; EVC(NM_001306090) 1;
EVC(NM_001306092) 1;
FGFR1(NM_001354367) 18; FGFR1(NM_001354369) 18;

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Prod test, SKEL PANEL 5
ARUP Accession: 22-229-107802
Patient Identifiers: 41765
Visit Number (FIN): 42090
Page 2 of 3 | Printed: 8/17/2022 12:56:19 PM

FGFR1(NM_001354370) 17; DYM(NM_001353212) 14; DYM(NM_001353213) 14; DYM(NM_001353214) 14; DYM(NM_001353215) 14; DYM(NM_001374428) 15; DYM(NM_001374429) 14; DYM(NM_001374430) 14 18; DYM(NM_001374431) 14; DYM(NM_001374432) 13; DYM(NM_001374433) 17; DYM(NM_001374441) 9; NEK1(NM_001374422) 17; NEK1(NM_001374423) 16; POR (NM_001382655) 3

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Skeletal Dysplasia Panel Specimen	22-229-107802	8/17/2022 12:04:00 PM	8/17/2022 12:04:30 PM	8/17/2022 12:36:00 PM
Skeletal Dysplasia Panel Interp	22-229-107802	8/17/2022 12:04:00 PM	8/17/2022 12:04:30 PM	8/17/2022 12:35:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Prod test, SKEL PANEL 5
ARUP Accession: 22-229-107802
Patient Identifiers: 41765
Visit Number (FIN): 42090
Page 3 of 3 | Printed: 8/17/2022 12:56:19 PM